U.S. Markets closed

Calliditas Therapeutics AB (publ) (CALT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
17.52-0.49 (-2.72%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close18.01
Bid8.86 x 1000
Ask20.19 x 900
Day's Range17.40 - 18.40
52 Week Range12.55 - 33.19
Avg. Volume7,641
Market Cap467.469M
Beta (5Y Monthly)1.51
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est61.75
  • PR Newswire

    Calliditas Therapeutics establishes a U.S. At-the-Market Program

    Calliditas Therapeutics AB (publ) (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas" or "the Company") today announced that it has filed with the U.S. Securities and Exchange Commission (the "SEC") a registration statement including a prospectus ("Prospectus") relating to a U.S. At-the-Market framework of up to an aggregate amount of $75,000,000, pursuant to which the Company may, at its option, sell American Depositary Shares ("ADSs") in the United States at market price, from time to time,

  • GlobeNewswire

    Celularity Appoints Industry Leader Diane Parks to its Board of Directors

    Pharmaceutical and Biotech Industry Veteran Brings Significant Strategic Development and Commercialization Expertise Launching New Cellular TherapiesFLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an executive with deep experience in the commercializati

  • Benzinga

    Calliditas' Kinpeygo Receives CHMP Backing For Kidney Disease

    The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional approval for Calliditas Therapeutics AB's (NASDAQ: CALT) Kinpeygo for primary immunoglobulin A (IgA) nephropathy (IgAN). The opinion covers adult patients at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/gram. Also See: Calliditas Shares Rally After FDA's Accelerated Approval For Budesonide For Kidney Disease. If